Geoff S. Higgins
Oxford, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 60 publications
SHLD2 loss is a synthetic vulnerability to Polθ inhibition combined with radiotherapy.
Journal: Science advances
Published: June 12, 2026
The pharmacological profile of ART6043, a first-in-class clinical DNA polymerase theta polymerase domain inhibitor potentiating PARP inhibitor efficacy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 06, 2026
Outcomes Following Radiotherapy for Oligoprogressive NSCLC on Immune Checkpoint Inhibitors: A Real-World, Multinational Experience.
Journal: Cancers
Published: November 28, 2025
Proton pencil beam scanning lattice radiotherapy: technical implementation and comparison against photon-based delivery.
Journal: The British journal of radiology
Published: August 06, 2025
UPR-induced intracellular C5aR1 promotes adaptation to the hypoxic tumour microenvironment.
Journal: Cell death & disease
Published: November 08, 2024
Combined Oxygen-Enhanced MRI and Perfusion Imaging Detect Hypoxia Modification from Banoxantrone and Atovaquone and Track Their Differential Mechanisms of Action.
Journal: Cancer research communications
Published: June 12, 2024
The Proteogenomics of Prostate Cancer Radioresistance.
Journal: Cancer research communications
Published: May 26, 2024
Molecular analysis of archival diagnostic prostate cancer biopsies identifies genomic similarities in cases with progression post-radiotherapy, and those with de novo metastatic disease.
Journal: The Prostate
Published: January 11, 2024
Repurposing radiosensitising medicines for radiotherapy: an overview.
Journal: BMJ oncology
Published: September 15, 2023
Biallelic FBXW7 knockout induces AKAP8-mediated DNA damage in neighbouring wildtype cells.
Journal: Cell death discovery
Published: February 22, 2023
Last Updated: 09/26/2026